RCM
TCRT icon

Rotella Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

Rotella Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-74
Closed -$29K – 434
2014
Q3 		$29K Sell
74
-52
-41% -$25.1K 0.03% 278
2014
Q2 		$76K Buy
+126
New +$70.2K 0.06% 265

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rotella Capital Management's TCRT Position: Q4 2014 in Review

Rotella Capital Management sold out of Alaunos Therapeutics (TCRT) in Q4 2014, closing a stake of 74 shares — an estimated $29K sold.

Rotella Capital Management first reported a position in TCRT in Q2 2014 and held it in 2 quarters. The position peaked at $76K in Q2 2014. 85 funds tracked by Wall St. Rank hold TCRT as of Q4 2014.

  • Rotella Capital Management reported no remaining Alaunos Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Rotella Capital Management sold 74 Alaunos Therapeutics shares in Q4 2014, an estimated $29K.
  • Rotella Capital Management first reported a position in Alaunos Therapeutics in Q2 2014 and held it in 2 quarters.
  • Rotella Capital Management's Alaunos Therapeutics position peaked at $76K in Q2 2014.
  • 85 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2014.

Based on Rotella Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.